DDD vs PRLB: How DDD and Protolabs manufactures custom parts on demand Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DDD and PRLB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DDD and PRLB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

3D Systems Corporation is one of the original additive manufacturing companies, offering a broad portfolio of 3D printers, print materials, software, and on-demand manufacturing services. It reports in two segments. Healthcare Solutions covers dental, medical devices, and regenerative technologies like bioprinting, and in Q1 2026 grew about 21% year over year (roughly $50 million) on strength in Dental and Med Tech, each up over 20%. Industrial Solutions serves aerospace, defense, and general manufacturing and grew more modestly (roughly $45 million). Total Q1 2026 revenue was about $95.5 million, up ~1% reported but ~11% excluding divestitures, and healthcare has grown to a scale that now rivals the industrial business.

Full DDD guide

Protolabs manufactures custom parts on demand, using injection moulding, CNC machining, sheet metal and 3D printing, with an automated quoting system that turns an uploaded CAD file into a price and a lead time.

Full PRLB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DDD drivers: Healthcare as the growth engine; Margin recovery and cost discipline.
• PRLB drivers: Digital quoting is the actual moat; Multiple processes under one supplier.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is that 3D Systems is a small, not-yet-consistently-profitable turnaround, so the thesis depends on execution that has not been fully proven. For PRLB, growth has slowed considerably from the company's earlier trajectory, and Xometry has competed aggressively with an asset-light marketplace model that carries lower fixed costs.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DDD if you believe its drivers more; PRLB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DDD and PRLB guides.

DDD. Figures are approximate and tied to the asOf date; verify live numbers before acting. Because 3D Systems is not consistently GAAP-profitable, traditional earnings multiples are not very meaningful, and the stock trades more on revenue growth, margin trajectory, and cash burn than on a stable P/E. As a low-priced small cap it can be volatile and sensitive to a single quarter. Treat this as a turnaround valuation, where the key is whether improving margins and healthcare growth translate into durable free cash flow.

PRLB. Protolabs sits between a manufacturer and a software company, and the market has debated which multiple applies. Verify current revenue growth, margins and the mix between owned and network capacity.

Headline figures (approximate, Jul 2026): DDD shows revenue (q1 2026) ~$95.5 million, up ~1% reported (or ~11% excluding divestitures) year over year, segment mix Healthcare ~$50 million (up ~21%) roughly matched Industrial ~$45 million, gross margin (q1 2026, non-gaap) ~36%, up from ~30% a year earlier on richer product mix, profitability GAAP EPS loss narrowed to ~$(0.03); adjusted EBITDA slightly positive (~$2 million); PRLB shows business model On-demand custom manufacturing with automated quoting, processes Injection moulding, CNC machining, sheet metal, 3D printing, cost structure Owns factories, so fixed costs are meaningful, competitive pressure Asset-light marketplace rivals; verify current growth.

DDD and PRLB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DDD and PRLB exposure against your real portfolio. It is not an investment adviser.